MedPath

Prospective evaluation of the significance of dose adjustment in rituximab plus CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma

Phase 2
Recruiting
Conditions
Diffuse large B cell lymphoma
Registration Number
JPRN-UMIN000025569
Lead Sponsor
Tochigi Cancer Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
62
Inclusion Criteria

Not provided

Exclusion Criteria

(1)testis,CNS invasion/IVL,transformation from loe grade lymphoma (2)HIV infection (3)severe infection (4)Psycological disorder like schizophrenia. (5)Active or non-curable synchronous malignancy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath